• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

STARMEN: progress in membranous nephropathy?

作者信息

Chapman Fiona A, Dhaun Neeraj

机构信息

Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK; University/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK; University/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

出版信息

Kidney Int. 2021 May;99(5):1242-1243. doi: 10.1016/j.kint.2021.01.025.

DOI:10.1016/j.kint.2021.01.025
PMID:33892865
Abstract
摘要

相似文献

1
STARMEN: progress in membranous nephropathy?
Kidney Int. 2021 May;99(5):1242-1243. doi: 10.1016/j.kint.2021.01.025.
2
The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.STARMEN 试验：重新思考钙调磷酸酶抑制剂在膜性肾病中的治疗。
Kidney Int. 2021 Apr;99(4):811-813. doi: 10.1016/j.kint.2020.11.019.
3
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
4
Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy.个性化磷脂酶A2受体抗体驱动的利妥昔单抗治疗膜性肾病策略
Kidney Int. 2021 Apr;99(4):1023-1024. doi: 10.1016/j.kint.2020.12.029.
5
Case report: Successful treatment of refractory membranous nephropathy with telitacicept.病例报告：替利泰塞普特成功治疗难治性膜性肾病。
Front Immunol. 2023 Oct 17;14:1268929. doi: 10.3389/fimmu.2023.1268929. eCollection 2023.
6
Low-dose Rituximab Monotherapy or in Combination with Tacrolimus Is Effective in Primary Membranous Nephropathy.低剂量利妥昔单抗单药治疗或联合他克莫司对原发性膜性肾病有效。
Kidney360. 2020 Dec 18;2(2):336-338. doi: 10.34067/KID.0004672020. eCollection 2021 Feb 25.
7
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.他克莫司联合皮质类固醇与改良庞蒂切利方案治疗特发性膜性肾病的随机对照试验
Nephrology (Carlton). 2016 Feb;21(2):139-46. doi: 10.1111/nep.12569.
8
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.利妥昔单抗、低剂量环磷酰胺和泼尼松联合治疗特发性膜性肾病：病例系列
BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.
9
Role of Tacrolimus only therapy in modified Ponticelli regimen resistant idiopathic membranous glomerulonephritis.他克莫司单一疗法在改良的庞蒂切利方案抵抗性特发性膜性肾小球肾炎中的作用
Nephrology (Carlton). 2015 Jan;20(1):44-6. doi: 10.1111/nep.12341.
10
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.磷脂酶A2受体（PLA2R）抗体相关膜性肾病的免疫缓解：环磷酰胺与利妥昔单抗对比
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.